Table 2.
Efficacy of regorafenib or fruquintinib plus sintilimab in metastatic MSS colorectal cancer.
| Parameter | Best response | ORR | P | DCR | P | Median PFS (95%CI) | P | Median OS (95%CI) | P | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | |||||||||
| Total | 0 | 10 | 41 | 21 | 10/72 (13.9) | 51/72 (70.8) | 4.2 (2.9-5.5) | 10.5 (8.6-12.4) | ||||
| Treatment programs | 0.565 | 0.012 | 0.434 | 0.486 | ||||||||
| RS | 0 | 5 | 20 | 17 | 5/42 (11.9) | 25/42 (59.5) | 3.5 (2.2-4.8) | 11.0 (7.0-15.0) | ||||
| FS | 0 | 5 | 21 | 4 | 5/30 (16.7) | 26/30 (86.7) | 5.5 (3.5-7.5) | 10.5 (3.8-17.2) | ||||
| Tumor site | 0.561 | 0.264 | 0.289 | 0.646 | ||||||||
| Left colon | 0 | 7 | 29 | 18 | 7/54 (13.0) | 36/54 (66.7) | 3.6 (2.5-4.7) | 11.0 (8.9-13.1) | ||||
| Right colon | 0 | 3 | 10 | 3 | 3/16 (18.8) | 13/16 (81.3) | 7.0 (1.1-12.9) | 10.0 (4.7-15.3) | ||||
| KRAS status | 0.281 | 0.777 | 0.784 | 0.665 | ||||||||
| Wide type | 0 | 6 | 18 | 8 | 6/32 (18.8) | 24/32 (75.0) | 4.5 (3.2-5.4) | 11.0 (8.0-14.0) | ||||
| Mutant | 0 | 3 | 20 | 9 | 3/32 (9.4) | 23/32 (71.9) | 5.0 (2.9-7.1) | 10.5 (7.4-13.6) | ||||
| Metastatic site | 0.140 | 0.658 | 0.075 | 0.016 | ||||||||
| Liver | 0 | 4 | 28 | 12 | 4/44 (9.1) | 32/44 (72.7) | 3.5 (2.4-4.6) | 10.0 (7.4-12.6) | ||||
| Without liver | 0 | 6 | 13 | 9 | 6/28 (21.4) | 19/28 (67.9) | 4.5 (1.5-7.5) | 26.0 (8.8-43.2) | ||||
| Prior R therapy | 0.338 | 0.713 | 0.483 | 0.213 | ||||||||
| Yes | 0 | 0 | 8 | 2 | 0 | 8/10 (80.0) | 3.6 (2.5-4.7) | 10.0 (5.9-14.1) | ||||
| No | 0 | 10 | 33 | 19 | 10/62 (16.1) | 43/62 (69.4) | 4.3 (2.6-6.0) | 11.3 (7.9-14.7) | ||||
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; PFS, progression free survival; OS, overall survival. Bold values: P<0.05.